ACT : Analysis & Opinions

  1. All Quiet On The Market Front: Dow, S&P 500, Nasdaq Virtually ...

    November 12, 2014
  2. Wall Street's Latest Tax Craze... And How To Profit

    September 18, 2014
    A couple weeks ago in StreetAuthority Daily, we talked about some of Corporate America's latest financial engineering ...
  3. Capitalize On Wall Street's Latest Tax Craze

    September 18, 2014
    A couple weeks ago in StreetAuthority Daily, we talked about some of Corporate America's latest financial engineering ...
  4. Tight Consolidation Breakouts To Watch

    September 4, 2014
    Keep an eye on these four stocks for near-term consolidation breakouts.
  5. The Best Health Care Stock To Own Right Now

    July 24, 2014
    Although investing is about making money, I've noticed that losses are what really stick out in people's minds. If ...
  6. Is This The Best Health Care Stock To Own Right Now?

    July 24, 2014
    Although investing is about making money, I've noticed that losses are what really stick out in people's minds. If ...
  7. 3 Absolute Must-Own Dividend Aristocrats

    July 22, 2014
    What's your dividend style? Do you seek out the highest dividend yields, or stocks with the most impressive track record ...
  8. Four Upside Triangle Chart Pattern Breakouts

    May 28, 2014
    These four stocks just broke out of triangle chart patterns and provide upside targets as well as defined stop levels.
  9. Ten Money Managers Worth Following

    December 23, 2013
    Generally speaking, most retail investors along with the media outlets tend to closely follow the moves of well-known investors ...
  10. These Are America's Fastest-Growing Blue Chips

    December 4, 2013
    As company executives sit down to establish their 2014 strategies, they're faced with a sobering prospect: The U.S. economy ...
  11. Big Pharma Faces 'Pay For Delay' Lawsuits

    June 21, 2013
    Unless you follow the pharmaceutical and biotech sectors, it’s likely that you’ve never heard of pay to delay. Instead of ...
  12. A Good Deal For Actavis, But Warner Chilcott Goes A Little Cheap

    May 21, 2013
    Actavis gets a very useful asset, while Warner Chilcott shareholders get a decent exit.
  13. Teva Still Too Cheap, But Still Too Uncertain

    May 3, 2013
    Teva's present-day momentum is weak, but the value could appeal to patient long-term investors.
Trading Center